FDA investigating Matria Healthcare, other firms, for subcutaneous infusion of terbutaline.
This article was originally published in The Gray Sheet
Executive Summary
FDA INVESTIGATING TERBUTALINE DELIVERY VIA INFUSION PUMPS BY MATRIA, OTHER FIRMS, the agency notes in its response to a National Women's Health Network's petition to enjoin Matria Healthcare from marketing and distributing subcutaneous infusion pumps for the management of preterm labor. The agency reports that it is "investigating the activities of Matria and other providers of home health care services" with respect to their promoting terbutaline for preventing preterm labor.